What is Ainos?
Founded in 1984, Ainos operates as a diversified medtech enterprise specializing in the intersection of diagnostics and preventative medicine. The company maintains a robust portfolio that includes novel point-of-care testing platforms, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine. By integrating these advanced modalities, Ainos addresses critical gaps in clinical care, providing healthcare providers with actionable data and patients with targeted treatment options. Its strategic focus on synthetic RNA technology places the firm at the forefront of the next generation of medical interventions, effectively bridging the gap between laboratory research and bedside application.
How much funding has Ainos raised?
Ainos has raised a total of $12.8M across 3 funding rounds:
Stock Offering
$3.2M
Debt
$600K
Share Placement
$9M
Stock Issuance/Offering (2008): $3.2M, investors not publicly disclosed
Debt (2016): $600K, investors not publicly disclosed
Share Placement (2024): $9M, investors not publicly disclosed
Key Investors in Ainos
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Ainos?
With the successful completion of this major enterprise-level funding, Ainos is set to enter a pivotal phase of operational scaling and product commercialization. The company intends to utilize these resources to expand its clinical trial pipeline and enhance its manufacturing capabilities for its proprietary RNA-driven therapeutics. As the medtech sector continues to evolve toward personalized and rapid-response diagnostics, Ainos is well-positioned to capture significant market share. Future strategic milestones will likely involve the regulatory advancement of its point-of-care testing suite and the potential expansion of its therapeutic reach into new clinical indications, ensuring sustained growth and long-term value creation for stakeholders.
See full Ainos company page
